GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Inventory-to-Revenue

JW (Cayman) Therapeutics Co (HKSE:02126) Inventory-to-Revenue : 0.50 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. JW (Cayman) Therapeutics Co's Average Total Inventories for the quarter that ended in Jun. 2024 was HK$46.3 Mil. JW (Cayman) Therapeutics Co's Revenue for the six months ended in Jun. 2024 was HK$93.5 Mil. JW (Cayman) Therapeutics Co's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.50.

JW (Cayman) Therapeutics Co's Inventory-to-Revenue for the quarter that ended in Jun. 2024 increased from Dec. 2023 (0.44) to Dec. 2023 (0.50)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. JW (Cayman) Therapeutics Co's Days Inventory for the six months ended in Jun. 2024 was 182.08.

Inventory Turnover measures how fast the company turns over its inventory within a year. JW (Cayman) Therapeutics Co's Inventory Turnover for the quarter that ended in Jun. 2024 was 1.00.


JW (Cayman) Therapeutics Co Inventory-to-Revenue Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Inventory-to-Revenue Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory-to-Revenue
Get a 7-Day Free Trial - - 0.53 0.26 0.22

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.43 0.47 0.44 0.50

Competitive Comparison of JW (Cayman) Therapeutics Co's Inventory-to-Revenue

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Inventory-to-Revenue falls into.



JW (Cayman) Therapeutics Co Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

JW (Cayman) Therapeutics Co's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (44.846 + 38.039) / 2 ) / 190.16
=41.4425 / 190.16
=0.22

JW (Cayman) Therapeutics Co's Inventory-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue (Q: Jun. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Jun. 2024 )) / count ) / Revenue (Q: Jun. 2024 )
=( (38.039 + 54.481) / 2 ) / 93.46
=46.26 / 93.46
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JW (Cayman) Therapeutics Co  (HKSE:02126) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

JW (Cayman) Therapeutics Co's Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2024 )/Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=46.26/46.367*365 / 2
=182.08

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

JW (Cayman) Therapeutics Co's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2024 ) / Average Total Inventories (Q: Jun. 2024 )
=46.367 / 46.26
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JW (Cayman) Therapeutics Co Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co Headlines

No Headlines